DENODO
2.6.2024 14:31:31 CEST | Business Wire | Press release
Denodo, a leader in data management is opening their new Middle East regional head office in Riyadh, Kingdom of Saudi Arabia (KSA) today. To inaugurate the office opening, Denodo is launching their first “Denodo Data Day” with Her Highness Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and delegates from Google Cloud, among others, as guest speakers. The new office will support new and existing Denodo customers and partners in the Middle East, providing them with direct access to the company’s experts in logical data management and AI-supported data solutions. This regional expansion is a testament to Denodo’s growing business and its customers in the region.
"We are thrilled to expand our presence in the Middle East with the opening of our new office in Riyadh, a city known for its rapid growth and innovation," said Ángel Viña, CEO and founder at Denodo. "Riyadh is host to a growing number of companies and government agencies, particularly in the technology, finance, and energy sectors – including the ambitious NEOM City. This new office will enable us to better serve our customers in the Middle East, providing them with our 'fearless data' approach to logical data management and the cutting-edge solutions they need to stay ahead in today's competitive market."
Denodo has made significant investments in AI and GenAI, which supports the Kingdom’s Vision 2030’s AI goals of making Saudi Arabia an international AI hub. Saudi Arabia is investing heavily in AI to diversify its economy. PwC recently published estimates that AI will contribute more than $135 billion to Saudi Arabia’s economy by 2030, which would lessen its reliance on revenue from oil. The Kingdom’s National Strategy aims for a global AI ranking of 15 by 2030. Recently, Saudi Arabia gained the top spot for AI government strategy. However, data management remains a hurdle. Traditional methods are complex and slow, hindering businesses seeking AI's potential in areas like customer experience.
“Saudi Arabia is the largest economy in the Middle East, and it’s going through an amazing period of growth and change,” said Gabriele Obino, regional vice president and general manager, Middle East, Denodo. “Denodo is a pioneer in logical data management, and we are offering local and regional organizations, in various industries including aviation, healthcare and Government, the opportunity to start or continue their digital transformations to modern cloud and GenAI-based data solutions.”
By fostering strong collaboration with key technology providers and systems integrators, such as the global cloud hyperscaler Google Cloud, Denodo demonstrates that its customers in the Middle East have access to the most innovative and comprehensive data solutions available, empowering them to make informed, data-driven decisions to help them stay ahead in today's competitive landscape.
Niall McDonagh, director, EMEA Public Sector, Google Cloud, emphasized the unique position of Google Cloud in Saudi Arabia: “As the only cloud provider with a dedicated region in Saudi Arabia, Google Cloud is uniquely positioned to support the digital transformation needs of this vibrant market. Our partnership with Denodo for the inaugural Denodo Data Day in Riyadh is a pivotal moment for us to showcase how our cloud solutions, coupled with Denodo’s logical data management technology, can drive significant advancements in key industries such as finance, healthcare, government, and education. We are also excited to highlight the capabilities of our Google Cloud Center of Excellence, which provides strategic guidance and cloud technology expertise.”
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602513059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom